Acromegaly and Gigantism Treatment Market Analysis By Product (Somatostatin Analogs, Growth Hormone Receptor Antagonist (GHRA), and Dopamine Agonist), By End User (Hospitals & Clinics, and Others) & Forecast
- PUBLISHED ON
- 4/3/2023
- NO OF PAGES
- 283
- CATEGORY
- Healthcare & Life Sciences
Acromegaly and gigantism are rare hormonal disorders that are caused by an excess of growth hormone in the body. Acromegaly is typically diagnosed in adults, while gigantism is usually diagnosed in children and adolescents.
The global acromegaly and gigantism treatment market is expected to grow significantly in the coming years, primarily due to the increasing prevalence of these conditions and the availability of advanced treatment options.
The most common treatment options for acromegaly and gigantism include surgery, radiation therapy, and medication. Surgery is often the first choice for treatment, as it can provide immediate relief of symptoms. Radiation therapy is usually used in cases where surgery is not an option or has not been successful. Medications such as somatostatin analogs, growth hormone receptor antagonists, and dopamine agonists are also commonly used to manage symptoms.
The key players operating in the acromegaly and gigantism treatment market include Novartis International AG, Pfizer Inc., Ipsen Biopharmaceuticals, Inc., Chiasma, Inc., and Amryt Pharma Plc. These companies are focusing on developing new and innovative treatment options to improve patient outcomes and reduce the side effects associated with current treatment options.
Overall, the acromegaly and gigantism treatment market is expected to experience steady growth in the coming years due to the increasing prevalence of these conditions and the availability of effective treatment options. However, the high cost of treatment and the limited availability of advanced treatment options in some regions may hinder market growth to some extent.
Report Scope
Report Attributes | Description |
Market Size in 2022 | USD 3.85 Billion |
Market Forecast in 2032 | USD 7.54 Billion |
CAGR % 2023-2031 | 6.4% |
Base Year | 2022 |
Historic Data | 2019-2021 |
Forecast Period | 2023-2031 |
Report USP | Production, Consumption, company share, company heatmap, company production capacity, growth factors and more |
Segments Covered | By Treatment Type, By End-user |
Regional Scope | North America, Europe, APAC, South America and Middle East and Africa |
Country Scope | U.S.; Canada; U.K.; Germany; France; Italy; Spain; Benelux; Nordic Countries; Russia; China; India; Japan; South Korea; Australia; Indonesia; Thailand; Mexico; Brazil; Argentina; Saudi Arabia; UAE; Egypt; South Africa; Nigeria |
Key Companies | Pfizer Inc., Novartis International AG, Ipsen Biopharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., Crinetics Pharmaceuticals, Inc., Chiasma, Inc., Strongbridge Biopharma plc, Amryt Pharma plc, Aeterna Zentaris Inc., Shire (now part of Takeda Pharmaceuticals) |
Segment Overview
The market segment for acromegaly and gigantism treatment includes various types of therapies and drugs used to manage the symptoms and underlying causes of these disorders. These conditions are caused by an excess of growth hormone, which can lead to abnormal growth and physical changes in the body.
The most common treatment for acromegaly and gigantism is the use of medications to lower the levels of growth hormone in the body. These medications include somatostatin analogs, which work by inhibiting the release of growth hormone from the pituitary gland, and dopamine agonists, which can reduce the production of growth hormone.
In addition to medication, other treatment options may include surgery to remove tumors or other growths that are causing the excess production of growth hormone. Radiation therapy may also be used to destroy tumors and reduce the production of growth hormone.
The market for acromegaly and gigantism treatment is expected to grow in the coming years, driven by an increasing awareness of these disorders and improved diagnostic techniques. Advances in medical technology and the development of new drugs and therapies are also expected to drive growth in the market.
Geographically, the market for acromegaly and gigantism treatment is likely to be concentrated in developed regions with strong healthcare infrastructure, such as North America and Europe. However, emerging markets in Asia and Latin America may also present growth opportunities as awareness of these conditions increases and healthcare access improves.
Geographical Overview
The treatment market for acromegaly and gigantism is a global market, with a focus on developed countries such as the United States, Europe, and Japan. However, the prevalence of the condition and access to healthcare can also affect the market in developing countries.
In terms of market share, North America currently dominates the market due to the high prevalence of acromegaly and gigantism, increased awareness and diagnosis rates, and availability of advanced treatment options. Europe is the second-largest market, with a significant share due to the presence of key players and high demand for effective therapies.
Asia Pacific is expected to be the fastest-growing market due to the increasing incidence of acromegaly and gigantism in countries such as China and India, growing healthcare infrastructure, and increasing awareness about the condition. Other regions such as Latin America and the Middle East and Africa are also expected to experience growth due to improving healthcare facilities and rising awareness.
Overall, the acromegaly and gigantism treatment market is expected to grow significantly in the coming years, driven by the increasing incidence of these conditions and the development of new treatment options.
COVID Impact
The COVID-19 pandemic has impacted the acromegaly and gigantism treatment market in various ways. The disruption in healthcare services and the diversion of healthcare resources towards COVID-19 patients have negatively impacted the market growth.
The pandemic has resulted in reduced patient visits to healthcare facilities, including endocrinology clinics, which has impacted the diagnosis and treatment of acromegaly and gigantism. Furthermore, the limited availability of diagnostic tests and imaging facilities during the pandemic has further hindered the market growth.
Additionally, the pandemic has caused disruptions in the supply chain and manufacturing of drugs used for the treatment of acromegaly and gigantism. This has led to the shortage of drugs and increased prices of available drugs, further impacting the market growth.
On the other hand, the increasing awareness among people about the importance of maintaining a healthy lifestyle has led to an increased demand for preventive measures against diseases such as acromegaly and gigantism. Moreover, the development of telemedicine and virtual healthcare services has facilitated the remote diagnosis and treatment of acromegaly and gigantism patients, which has partially mitigated the negative impact of the pandemic on the market.
Overall, the COVID-19 pandemic has negatively impacted the acromegaly and gigantism treatment market, but the market is expected to recover gradually with the resumption of normal healthcare services and the availability of effective vaccines.
Competitive Analysis
Acromegaly and gigantism are rare hormonal disorders caused by excess growth hormone production. There are several treatment options available for these conditions, including surgery, medication, and radiation therapy. The market for acromegaly and gigantism treatment is highly competitive, with several major players competing for market share.
Some of the key players in the acromegaly and gigantism treatment market include:
1. Pfizer Inc.
2. Novartis International AG
3. Ipsen Biopharmaceuticals Inc.
4. Teva Pharmaceutical Industries Ltd.
5. Crinetics Pharmaceuticals, Inc.
6. Chiasma, Inc.
7. Strongbridge Biopharma plc
8. Amryt Pharma plc
9. Aeterna Zentaris Inc.
10. Shire (now part of Takeda Pharmaceuticals)
These companies offer a variety of treatment options, including somatostatin analogs, growth hormone receptor antagonists, dopamine agonists, and other medications. In addition, some companies offer surgical and radiation treatments for acromegaly and gigantism.
In recent years, there has been a trend towards developing innovative therapies for acromegaly and gigantism, including new medications and targeted therapies. For example, Crinetics Pharmaceuticals is developing a novel oral nonpeptide somatostatin receptor agonist for acromegaly, and Chiasma, Inc. has developed a novel oral octreotide capsule for the treatment of acromegaly.
Overall, the acromegaly and gigantism treatment market is expected to continue to grow in the coming years, as more effective and innovative treatments are developed and as the prevalence of these conditions increases due to factors such as an aging population.
Quality Assurance Process
- We Market Research’s Quality Assurance program strives to deliver superior value to our clients.
We Market Research senior executive is assigned to each consulting engagement and works closely with the project team to deliver as per the clients expectations.
Market Research Process
We Market Research monitors 3 important attributes during the QA process- Cost, Schedule & Quality. We believe them as a critical benchmark in achieving a project’s success.
To mitigate risks that can impact project success, we deploy the follow project delivery best practices:
- Project kickoff meeting with client
- Conduct frequent client communications
- Form project steering committee
- Assign a senior SR executive as QA Executive
- Conduct internal editorial & quality reviews of project deliverables
- Certify project staff in SR methodologies & standards
- Monitor client satisfaction
- Monitor realized value post-project
Case Study- Automotive Sector
One of the key manufacturers of automotive had plans to invest in electric utility vehicles. The electric cars and associated markets being a of evolving nature, the automotive client approached We Market Research for a detailed insight on the market forecasts. The client specifically asked for competitive analysis, regulatory framework, regional prospects studied under the influence of drivers, challenges, opportunities, and pricing in terms of revenue and sales (million units).
Solution
The overall study was executed in three stages, intending to help the client meet its objective of precisely understanding the entire market before deciding on an investment. At first, secondary research was conducted considering political, economic, social, and technological parameters to get a gist of the various aspects of the market. This stage of the study concluded with the derivation of drivers, opportunities, and challenges. It also laid substantial emphasis on understanding and collecting data not only on a global scale but also on the regional and country levels. Data Extraction through Primary Research
The second stage involved primary research in which several market players and automotive parts suppliers were contacted to study their viewpoint concerning the development of their market and production capacity, clientele, and product line. This stage concluded in a brief understanding of the competitive ecosystem and also glanced through the strategies and pricing of the companies profiled.
Market Estimates and Forecast
In the final stage of the study, market forecasts for the electric utility were derived using multiple market engineering approaches. This data helped the client to get an overview of the market and accelerate the process of investment.
Case Study- ICT Sector
Business process outsourcing, being one of the lucrative markets from both supply- and demand- side, has appealed to various companies. One of the prominent corporations based out of Japan approached us with their requirements regarding the scope of the procurement outsourcing market for around 50 countries. Additionally, the client also sought key players operating in the market and their revenue breakdown in terms of region and application.
Business Solution
An exhaustive market study was conducted based on primary and secondary research that involved factors such as labor costs in various countries, skilled and technical labors, manufacturing scenario, and their respective contributions in the global GDP. A comparative study of the market was conducted from both supply- and demand side, with the supply-side comprising of notable companies, such as GEP, Accenture, and others, that provide these services. On the other hand, large manufacturing companies from them demand-side were considered that opt for these services.
Conclusion
The report aided the client in understanding the market trends, including country-level business scenarios, consumer behavior, and trends in 50 countries. The report also provided financial insights of crucial players and detailed market estimations and forecasts till 2033.
}})
Select a license type that suits your business needs
US $4250
Only Four Thousand Two Hundred Fifty US dollar
- 1 User access
- 15% Additional Free Customization
- Free Unlimited post-sale support
- 100% Service Guarantee until achievement of ROI
US $5250
Only Five Thousand Two Hundred Fifty US dollar
- 5 Users access
- 25% Additional Free Customization
- Access Report summaries for Free
- Guaranteed service
- Dedicated Account Manager
- Discount of 20% on next purchase
- Get personalized market brief from Lead Author
- Printing of Report permitted
- Discount of 20% on next purchase
- 100% Service Guarantee until achievement of ROI
US $6250
Only Six Thousand Two Hundred Fifty US dollar
- Unlimited User Access
- 30% Additional Free Customization
- Exclusive Previews to latest or upcoming reports
- Discount of 30% on next purchase
- 100% Service Guarantee until achievement of ROI